Patent 11746157 was granted and assigned to Janssen Biotech on September, 2023 by the United States Patent and Trademark Office.
The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.